Joan H. Schiller, MD
Chair, Scientific Steering Committee
Dr. Joan H. Schiller is widely published and internationally recognized for her work in lung cancer clinical research. She is a professor in the Department of Medicine, Section of Hematology Oncology at the University of Virginia. Previously, she was Deputy Director of Clinical Investigation for the Inova Schar Cancer Institute in Fairfax, Virginia. Dr. Schiller is also the former division chief of Hematology/Oncology at the University of Texas-Southwestern Medical Center and Deputy Director of the Simmons Comprehensive Cancer Center in Dallas, where she held the Andrea L. Simmons Distinguished Chair in Cancer Research. Dr. Schiller has served as an editor for the Journal of Clinical Oncology; a board member for the International Association for the Study of Lung Cancer, and the principal investigator on many national clinical trials for lung cancer. She also served as chairperson of the Thoracic Oncology Committee of the Eastern Co-operative Oncology Group for many years until stepping down from that position in 2012, and currently serves on the NCI Board of Scientific Counselors - Clinical Sciences and Epidemiology.
Dr. Schiller graduated from the University of Illinois Medical School and completed her internship and residency in internal medicine at Northwestern Memorial Hospital in Chicago. She then completed a clinical fellowship in the Department of Human Oncology at the University of Wisconsin Comprehensive Cancer Center where she became the Melanie Heald Professor in the Department of Medicine, Section of Medical Oncology, and subsequently served as head of the Lung Cancer Program at the University of Wisconsin Comprehensive Cancer Center.
Dr. Schiller’s research has generated well over 200 publications that she has authored or co-authored, including articles, abstracts, book chapters, books, reviews and invited manuscripts.
Dr. Schiller was founder and President of Free to Breathe, a national advocacy organization aimed at raising awareness and funding for lung cancer. Free to Breathe awarded over $9.4 million dollars in research funds to close to 50 investigators between 2005 and 2017, before its merger with Lung Cancer Research Foundation.